Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen

NCT00293215 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Abnormal distribution and lack of tumor targeting were observed.

Conditions

Neoplasms

Interventions

DRUG: 111-Indium-CMD-193
DRUG: CMD-193

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]